The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies

Highlights • Hematologic malignancies respond to histone deacetylase (HDAC) inhibitors. • Associated adverse events include thrombocytopenia, fatigue, nausea, vomiting, and anorexia. • HDAC inhibitors are also associated with AEs unique to their treatment that may not be considered class-specific ef...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2016-02, Vol.43, p.58-66
Hauptverfasser:	Duvic, Madeleine, Dimopoulos, Meletios
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Apoptosis - drug effects Cell Cycle - drug effects Clinical trial Depsipeptides - pharmacology Disease Management HDAC Hematologic malignancies Hematologic Neoplasms - metabolism Hematologic Neoplasms - pathology Hematology, Oncology and Palliative Medicine Histone Acetyltransferases - antagonists & inhibitors Histone Acetyltransferases - metabolism Histone deacetylase inhibitors Histone Deacetylase Inhibitors - pharmacology Histone Deacetylases - metabolism Humans Hydroxamic Acids - pharmacology Lymphoma, T-Cell, Cutaneous - metabolism Lymphoma, T-Cell, Cutaneous - pathology Protein Folding - drug effects Safety Treatment Outcome Vorinostat
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Hematologic malignancies respond to histone deacetylase (HDAC) inhibitors. • Associated adverse events include thrombocytopenia, fatigue, nausea, vomiting, and anorexia. • HDAC inhibitors are also associated with AEs unique to their treatment that may not be considered class-specific effects. • Vorinostat and other HDAC inhibitors are promising options for hematologic malignancies with manageable AE profiles.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2015.04.003